SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE)
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The investigators wish to investigate whether enhancement of SWS, which is seen after a drug
called sodium oxybate, reduces the impact of sleep disruption in CFS on daytime function,
specifically sleepiness and mental performance. This is a safe and well-tolerated drug that
is licensed for excessive daytime sleepiness (EDS) and cataplexy associated with narcolepsy.
The investigators will study 12 patients diagnosed with CFS using international diagnostic
guidelines. The investigators will record overnight sleep with EEG (brainwave) measurement on
the 1st and 4th nights of a 4 night period during which sodium oxybate and placebo will be
taken nightly, and the investigators will measure next-day sleepiness, mental performance and
fatigue, and compare drug and placebo nights.